Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY1902607 Including the Relative Bioavailability Between Different Pharmaceutical Formulations and the Effect of Food on the Pharmacokinetics of BAY1902607 in Healthy Men
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2018
At a glance
- Drugs BAY 1902607 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Bayer
- 02 Aug 2018 Status changed from active, no longer recruiting to completed.
- 08 Jun 2018 Planned End Date changed from 7 Jun 2018 to 19 Jul 2018.
- 09 May 2018 Planned End Date changed from 15 Jun 2018 to 7 Jun 2018.